Cargando…

Old unsolved problems: when and how to treat silent ischaemia

Silent myocardial ischaemia (SMI) is defined as objective evidence of ischaemia without angina (or equivalent symptoms) in the presence of coronary artery disease, differing from silent coronary artery disease. Silent myocardial ischaemia represents the majority of episodes of myocardial ischaemia a...

Descripción completa

Detalles Bibliográficos
Autores principales: Indolfi, Ciro, Polimeni, Alberto, Mongiardo, Annalisa, De Rosa, Salvatore, Spaccarotella, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904061/
https://www.ncbi.nlm.nih.gov/pubmed/33654471
http://dx.doi.org/10.1093/eurheartj/suaa141
_version_ 1783654855696449536
author Indolfi, Ciro
Polimeni, Alberto
Mongiardo, Annalisa
De Rosa, Salvatore
Spaccarotella, Carmen
author_facet Indolfi, Ciro
Polimeni, Alberto
Mongiardo, Annalisa
De Rosa, Salvatore
Spaccarotella, Carmen
author_sort Indolfi, Ciro
collection PubMed
description Silent myocardial ischaemia (SMI) is defined as objective evidence of ischaemia without angina (or equivalent symptoms) in the presence of coronary artery disease, differing from silent coronary artery disease. Silent myocardial ischaemia represents the majority of episodes of myocardial ischaemia at Holter monitoring. During transient myocardial ischaemia, the symptoms appear after the contraction anomalies of the left ventricle and after the ECG changes. The cause of silent myocardial ischaemia is still not well established. The severity and duration of ischaemia have been theorized as important elements in the SMI mechanism. Another possible mechanism responsible for SMI is represented by changes in the perception of painful stimuli with an increased pain threshold. Finally, a neuronal dysfunction of the diabetic, in post-infarction or a cardiac neuronal ‘stunning’ could play a role in SMI. In the pre-stent era, the SMI was associated with a worse prognosis. In patients with diabetes mellitus, SMI seems to be more represented because autonomic dysfunction is present in this category of patients. In conclusion, SMI is more frequent than symptomatic ischaemia. However, despite the presence of countless studies on the subject, it is not clear today whether medical therapy has equalized the risk and what the real prognosis of SMI is.
format Online
Article
Text
id pubmed-7904061
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79040612021-03-01 Old unsolved problems: when and how to treat silent ischaemia Indolfi, Ciro Polimeni, Alberto Mongiardo, Annalisa De Rosa, Salvatore Spaccarotella, Carmen Eur Heart J Suppl Articles Silent myocardial ischaemia (SMI) is defined as objective evidence of ischaemia without angina (or equivalent symptoms) in the presence of coronary artery disease, differing from silent coronary artery disease. Silent myocardial ischaemia represents the majority of episodes of myocardial ischaemia at Holter monitoring. During transient myocardial ischaemia, the symptoms appear after the contraction anomalies of the left ventricle and after the ECG changes. The cause of silent myocardial ischaemia is still not well established. The severity and duration of ischaemia have been theorized as important elements in the SMI mechanism. Another possible mechanism responsible for SMI is represented by changes in the perception of painful stimuli with an increased pain threshold. Finally, a neuronal dysfunction of the diabetic, in post-infarction or a cardiac neuronal ‘stunning’ could play a role in SMI. In the pre-stent era, the SMI was associated with a worse prognosis. In patients with diabetes mellitus, SMI seems to be more represented because autonomic dysfunction is present in this category of patients. In conclusion, SMI is more frequent than symptomatic ischaemia. However, despite the presence of countless studies on the subject, it is not clear today whether medical therapy has equalized the risk and what the real prognosis of SMI is. Oxford University Press 2020-11-18 /pmc/articles/PMC7904061/ /pubmed/33654471 http://dx.doi.org/10.1093/eurheartj/suaa141 Text en Published on behalf of the European Society of Cardiology. © The Author(s) 2020. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Articles
Indolfi, Ciro
Polimeni, Alberto
Mongiardo, Annalisa
De Rosa, Salvatore
Spaccarotella, Carmen
Old unsolved problems: when and how to treat silent ischaemia
title Old unsolved problems: when and how to treat silent ischaemia
title_full Old unsolved problems: when and how to treat silent ischaemia
title_fullStr Old unsolved problems: when and how to treat silent ischaemia
title_full_unstemmed Old unsolved problems: when and how to treat silent ischaemia
title_short Old unsolved problems: when and how to treat silent ischaemia
title_sort old unsolved problems: when and how to treat silent ischaemia
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904061/
https://www.ncbi.nlm.nih.gov/pubmed/33654471
http://dx.doi.org/10.1093/eurheartj/suaa141
work_keys_str_mv AT indolficiro oldunsolvedproblemswhenandhowtotreatsilentischaemia
AT polimenialberto oldunsolvedproblemswhenandhowtotreatsilentischaemia
AT mongiardoannalisa oldunsolvedproblemswhenandhowtotreatsilentischaemia
AT derosasalvatore oldunsolvedproblemswhenandhowtotreatsilentischaemia
AT spaccarotellacarmen oldunsolvedproblemswhenandhowtotreatsilentischaemia